TY - JOUR T1 - Clinical Significance of <em>PLA2G2A</em> Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1 JF - Anticancer Research JO - Anticancer Res SP - 3583 LP - 3588 DO - 10.21873/anticanres.15146 VL - 41 IS - 7 AU - SHINSUKE HATORI AU - KENTARO SAKAMAKI AU - TAKEHIKO YOKOHORI AU - YAYOI KIMURA AU - YUKIHIKO HIROSHIMA AU - ITARU HASHIMOTO AU - KEISUKE KOMORI AU - HAYATO WATANABE AU - KAZUKI KANO AU - HIROHITO FUJIKAWA AU - TORU AOYAMA AU - MASAKATSU NUMATA AU - TAKANOBU YAMADA AU - HIROSHI TAMAGAWA AU - NAOTO YAMAMOTO AU - TAKASHI OGATA AU - MANABU SHIZAWA AU - NORIO YUKAWA AU - SOICHIRO MORINAGA AU - YASUSHI RINO AU - MUNETAKA MASUDA AU - HIROSHI SAEKI AU - YOHEI MIYAGI AU - TAKASHI OSHIMA Y1 - 2021/07/01 UR - http://ar.iiarjournals.org/content/41/7/3583.abstract N2 - Background/Aim: This study aimed to evaluate the prognostic significance of PLA2G2A expression in patients with locally advanced gastric cancer (GC). Patients and Methods: PLA2G2A expression levels in cancerous tissue specimens and adjacent normal mucosa obtained from 134 patients with stage II/III GC who received adjuvant chemotherapy with S-1 after curative resection were measured using real-time quantitative polymerase chain reaction. Subsequently, the associations of PLA2G2A expression with clinicopathological features and survival were evaluated. Results: No association was observed between clinicopathological features and PLA2G2A expression levels. Overall survival was significantly longer in patients with high PLA2G2A expression levels (p=0.022). Multivariate analysis revealed that PLA2G2A expression was a significant, independent prognostic factor (hazard ratio=0.136; 95% confidence interval=0.0185-0.992; p=0.049). Conclusion: PLA2G2A mRNA expression may serve as a useful prognostic marker in patients with locally advanced GC who receive curative surgery and adjuvant chemotherapy with S-1. ER -